<DOC>
	<DOCNO>NCT01455857</DOCNO>
	<brief_summary>Phase 3 study examine whether treatment ITCA-650 60 mcg/day 40 mcg/day superior placebo add current therapy reduce HbA1c patient type 2 diabetes .</brief_summary>
	<brief_title>A Study Evaluate ITCA 650 Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>HbA1c 7.5 % 10 % On diet &amp; exercise , metformin ( MET ) , sulfonylurea ( SU ) thiazolidinedione ( TZD ) alone combination combine ( SU + TZD ) combination Met + SU , Met + TZD , Met + TZD + SU BMI 25 &amp; 45 kg/m2 take DPP4 inhibitor , exenatide , liraglutide , alpha glucosidase inhibitor , meglitinides insulin within last 3 month history pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>